Novel method for identifying specific marker sequences for prostate cancer
AssigneeProtagen AG
InventorsPeter Amersdorfer, Angelika Lueking, Axel Kowald, Bettina Schlick, Petra Massoner, Christof Seifart, Georg Schäfer, Helmut Klocker, Peter Schulz-Knappe, Klaus Marquart
Life of this patent
Estimating the term…
Abstract
The present invention relates to a novel method for identifying specific marker sequences for diagnosis of prostate cancer and/or for prognosis in prostate cancer, and to the use of the specific marker sequences identified with the aid of this method.
Claims18
1-16. (canceled)
A method for identifying specific marker sequences for diagnosis of prostate cancer and/or for prognosis in prostate cancer, comprising the following steps:
- a) selecting patients with prostate cancer and high inflammation values and/or patients with prostate cancer and low inflammation values,
- b) determining the interaction of a sample from the selected patients with marker sequences to be tested, wherein the marker sequences to be tested are placed on a solid support,
- c) selecting marker sequences that demonstrate an interaction, and
- d) determining whether the selected marker sequences distinguish between progressive and non-progressive prostate cancer.
Use of SPOP and/or partial sequences and/or homologues of SPOP and/or of STX18 and/or partial sequences and/or homologues of STX18 and/or of SPAST and/or partial sequences and/or homologues of SPAST for diagnosis of prostate cancer and/or for prognosis in prostate cancer and/or for stratification in prostate cancer.
Dependencies are inferred from the claim text.